Effects of Lys to Glu mutations in GsMTx4 on membrane binding, peptide orientation, and self-association propensity, as analyzed by molecular dynamics simulations

Biochimica Et Biophysica Acta
Kazuhisa NishizawaThomas M Suchyna

Abstract

GsMTx4, a gating modifier peptide acting on cationic mechanosensitive channels, has a positive charge (+5e) due to six Lys residues. The peptide does not have a stereospecific binding site on the channel but acts from the boundary lipids within a Debye length of the pore probably by changing local stress. To gain insight into how these Lys residues interact with membranes, we performed molecular dynamics simulations of Lys to Glu mutants in parallel with our experimental work. In silico, K15E had higher affinity for 1-palmitoyl-2-oleoyl-glycero-3-phosphocholine bilayers than wild-type (WT) peptide or any other mutant tested, and showed deeper penetration than WT, a finding consistent with the experimental data. Experimentally, the inhibitory activities of K15E and K25E were most compromised, whereas K8E and K28E inhibitory activities remained similar to WT peptide. Binding of WT in an interfacial mode did not influence membrane thickness. With interfacial binding, the direction of the dipole moments of K15E and K25E was predicted to differ from WT, whereas those of K8E and K28E oriented similarly to that of WT. These results support a model in which binding of GsMTx4 to the membrane acts like an immersible wedge that serves as ...Continue Reading

References

Jun 26, 2002·The Journal of Biological Chemistry·Robert E OswaldFrederick Sachs
Jun 28, 2005·Nucleic Acids Research·John C GordonAlexey Onufriev
Oct 24, 2006·Proceedings of the National Academy of Sciences of the United States of America·Maria A SpassovaDonald L Gill
Nov 14, 2006·Toxicon : Official Journal of the International Society on Toxinology·Kenton J Swartz
Jun 16, 2007·The Journal of Physical Chemistry. B·Siewert J MarrinkAlex H de Vries
Jan 18, 2008·Biophysical Journal·Susan L Duncan, Ronald G Larson
Jan 24, 2008·Biophysical Journal·Justin L MacCallumD Peter Tieleman
Oct 4, 2008·The Journal of Physiology·Ana GomisFélix Viana
Jan 10, 2009·European Biophysics Journal : EBJ·Annette C HurstBoris Martinac
Oct 7, 2009·Proceedings of the National Academy of Sciences of the United States of America·Anna C V Johansson, Erik Lindahl
Feb 6, 2010·Physiology·Frederick Sachs
Jun 16, 2010·PLoS Computational Biology·Semen O YesylevskyySiewert J Marrink
Nov 6, 2010·Nucleic Acids Research·UNKNOWN UniProt Consortium
Apr 2, 2011·PLoS Computational Biology·Cesar A LópezSiewert J Marrink
Jul 19, 2006·Journal of Physics. Condensed Matter : an Institute of Physics Journal·D Peter TielemanLuca Monticelli
Jun 24, 2011·Biochemistry·Chilman BaePhilip A Gottlieb
Mar 12, 2013·Biophysical Journal·Manami Nishizawa, Kazuhisa Nishizawa
Sep 14, 2013·The Journal of Chemical Physics·Pedro TarazonaFernando Bresme

❮ Previous
Next ❯

Citations

Jul 18, 2016·Journal of Molecular and Cellular Cardiology·Jinli WangThomas M Suchyna
Jan 12, 2017·Biophysical Journal·Radhakrishnan GnanasambandamThomas M Suchyna
Sep 27, 2018·Scientific Reports·Mohammad M ManeshiPhilip A Gottlieb
Jan 11, 2018·Biophysical Journal·Frederick Sachs

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.